It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-22 10:55:33 Source:worldViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Election 2024: Biden and the Democrats raised far less in April than Trump and the GOP
Next:At least 40 villagers shot dead in latest violence in Nigeria's conflict
You may also like
- Warner holds out IPL hot shot Fraser
- What to stream: 'Iron Claw,' 'Pretty Little Liars,' Ryan Castro
- Javier Assad pitches 6 innings as Cubs blank Brewers 5
- 1 dead, 6 wounded in Birmingham, Alabama, shooting, police say
- Cristiano Ronaldo to lead Portugal into record sixth European Championship
- What Trump's gag order means in his hush money case
- Teenager killed, 5 others injured in shooting in Buffalo
- Stock market today: Asian shares track Wall St's advance fueled by cooler jobs data
- Emma Hayes' first roster as coach of the US women's team includes 2 first